Analysis of tumor xenografts showed a substantial reduction of Ki-67 expression, as well as inhibition of phospho-Akt and/or phospho-ERK1/2 levels, suggesting that sorafenib-mediated lymphoma growth inhibition also involves a direct inhibition of cancer cell proliferation. This evidence concerns the gene AKT1 and neoplasm.